Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

Published:2017-08 Issue:2 Volume:152 Page:271-281
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Khunger Monica,Rakshit Sagar,Pasupuleti Vinay,Hernandez Adrian V.,Mazzone Peter,Stevenson James,Pennell Nathan A.,Velcheti Vamsidhar

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference28 articles.

1. Programmed death ligand-1 expression in non-small cell lung cancer;Velcheti;Lab Invest,2014

2. Managing immune checkpoint-blocking antibody side effects;Postow;Am Soc Clin Oncol Educ Book,2015

3. Toxicities of immunotherapy for the practitioner;Weber;J Clin Oncol,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 393 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis;Clinical and Translational Oncology;2024-09-09

2. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors;Academic Radiology;2024-09

3. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

4. Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study;ESMO Open;2024-08

5. Newer Immunosuppressants for Rheumatologic Disease;Rheumatic Disease Clinics of North America;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3